TAMPA, Fla., Aug. 1, 2019 /PRNewswire/ — DataLink Software (DataLink), a leading healthcare technology company, has partnered with Armor Correctional Health Services, Inc. to provide a newly launched population health platform for correctional facilities. The EvokeCorr solution assists providers in correctional facilities with key items such as clinical documentation, appointments, assessments, and referrals to ensure the wellness and quality of care.
EvokeCorr adds to DataLink’s portfolio of offerings that include value-based solutions for health plans, MSOs, ACOs, and IPAs. DataLink’s EvokeCorr solution enables correctional facilities with a one-source solution providing real-time data aggregation, health assessment, facility care and and billing details.
“EvokeCorr extends DataLink’s reach to providing care to patients in correctional facilities,” said RaeAnn Grossman, Chief Growth Officer of DataLink. “DataLink’s partnership with Armor Correctional Health Services continues our goal of improving the quality of patient care in all care settings.”
About DataLink Software
DataLink Software is a healthcare technology company that empowers better health through real-time data aggregation from disparate sources and systems, illuminates value-based performance transformation and management, and simplifies the next steps in the care journey by enabling an intelligent point-of-care solution for provider types across all settings. For more information about DataLink Software contact info@datalinksoftware.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/datalink-software-launches-the-evokecorr-platform-and-partners-with-armor-correctional-health-services-inc-300895001.html
SOURCE DataLink Software
WASHINGTON & BERLIN--(BUSINESS WIRE)--Association of Medical Device Reprocessors issued the following statement: Friday’s unanimous verdict…
Two New Analyses from SEQUOIA-HCM on Effect of Aficamten Between Patientswith Mild and Moderate-to-Severe Symptoms,…
Slowing of progression of disease observed via MRI at 24 months Improvements in outcomes and…
Deep, durable and consistent reductions in TTR were sustained at two years, following a one-time…
Data confirmed TX45’s tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in…
TORONTO, May 17, 2025 (GLOBE NEWSWIRE) -- Today, on DIPG Awareness Day, Brain Cancer Canada…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="181px" width="400px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
